Diffusion-Weighted Imaging-Based Differentiating between Benign and Malignant Ovarian Lesions

基于弥散加权成像的卵巢良恶性病变鉴别诊断

阅读:1

Abstract

BACKGROUND: Ovarian cancer is a common female malignancy frequently identified at advanced stages. Diffusion-weighted imaging (DWI) provides valuable information on structural traits of tissue and is used as an imaging biomarker in OST cancer prognosis. Post-processing of three-dimensional apparent diffusion coefficient (ADC) maps has proven useful in evaluating variable tumors, although its position in ovarian cancer prognosis is until now not well defined. Consequently, our foremost objective was to assess the sensitivity and efficiency of DWI (T1 and T2) and ADC maps in malignant and benign ovarian lesions prognosis. MATHERIALS AND METHODS: A total of 58 patients with undetermined ovarian masses in ultrasound were referred to MRI for more accurate diagnosis. The signals of DWI (qualitative) and ADC values (quantitative DWI) of the lesion components were analyzed separately. Student's t-test and receiver operating characteristic (ROC) curves were used to determine the ability of DWI and ADC in the discrimination between malignant and benign ovarian masses. RESULTS: Of the 58 masses, 33 have been benign, and 25 have been malignant. There was a decrease correlation between signal thing on T2W and ADC values in malignant as compared to benign masses. The DWI and T1 + GAD values in malignant tumors have been substantially higher than the ones in benign masses (P value < 0.0001). Additionally, our consequences suggest that a T1 cutoff value (1 × 10⁻≥ mm²/s) would possibly the quality factor to help discriminate between benign and malignant lesions. CONCLUSIONS: The mixture of DWI imaging with T1 + GAD values can beautify the diagnostic overall performance in discrimination among benign and malignant ovarian masses by increasing specificity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。